https://scholars.lib.ntu.edu.tw/handle/123456789/596931
標題: | Safety and efficacy of pegylated liposomal doxorubicinbased adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer | 作者: | Lien M.-Y. Liu L.-C. Wang H.-C. Yeh M.-H. Chen C.-J. Yeh S.-P. Bai L.-Y. Liao Y.-M. Lin C.-Y. Hsieh C.-Y. Lin C.-C. Li L.-Y. PO-HAN LIN Chiu C.-F. |
關鍵字: | Adjuvant chemotherapy; Anthracycline; Pegylated liposomal doxorubicin; Triplenegative breast cancer | 公開日期: | 2014 | 出版社: | International Institute of Anticancer Research | 卷: | 34 | 期: | 12 | 起(迄)頁: | 7319-7326 | 來源出版物: | Anticancer Research | 摘要: | Background/Aim: Pegylated liposomal doxorubicin (PLD) has been proven to be an effective antitumor drug for metastatic breast cancer, with less toxicity than conventional anthracycline. Our objective was to evaluate the efficacy and safety of PLD-based adjuvant chemotherapy compared to conventional chemotherapy for patients with stages I-III Triple-negative breast cancer (TNBC). Patients and Methods: A total of 162 patients, histologically proven to have TNBC at stages I-III between 2003 and 2010, were enrolled to evaluate the impact of PLD- and non-PLD-based adjuvant chemotherapy by using the end-pint of overall survival (OS) and relapse-free survival (RFS). Results: Forty-nine (30.2%) patients received PLD-based adjuvant chemotherapy and 113 (69.8%) a non-PLD regimen, including 84 (52%) patients receiving non-PLD anthracycline. The Kaplan-Meier calculation indicated no differences in RFS and OS between the PLD and non-PLD groups. Multivariate analysis adjusted for tumor size and lymph node status also revealed similar RFS (HR=0.86, 95% CI=0.43-1.73, p=0.678) and OS (HR=0.86, 95% CI=0.41-1.79, p=0.692) for PLD-based chemotherapy compared with non-PLD-based. Patients receiving PLD-based chemotherapy had a relatively lower incidence of grade 3-4 neutropenia (25% vs. 41.6%, respectively; p=0.054) and significantly higher incidence of hand-foot syndrome (16.3% vs. 4.4%, respectively; p=0.010). Conclusion: PLD-based adjuvant chemotherapy was as effective as conventional chemotherapy for patients with TNBC. PLD is an alternative for patients with TNBC when conventional anthracycline is inappropriate. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84918555748&partnerID=40&md5=0f512168db2b2991202e484da218cf59 https://scholars.lib.ntu.edu.tw/handle/123456789/596931 |
ISSN: | 0250-7005 | SDG/關鍵字: | cisplatin; cyclophosphamide; doxorubicin; epirubicin; fluorouracil; antineoplastic antibiotic; doxorubicin; macrogol derivative; adult; Article; cancer adjuvant therapy; cancer incidence; cancer radiotherapy; cancer recurrence; cancer staging; chemotherapy induced nausea and vomiting; drug efficacy; drug safety; fluorescence in situ hybridization; hand foot syndrome; heart failure; heart function; heart left ventricle contractility; human; lymph node; major clinical study; multiple cycle treatment; neutropenia; overall survival; post mastectomy radiation therapy; recurrence free survival; triple negative breast cancer; tumor volume; adjuvant chemotherapy; adverse effects; analogs and derivatives; chemically induced; clinical trial; disease free survival; female; Hand-Foot Syndrome; middle aged; mortality; neutropenia; pathology; Triple Negative Breast Neoplasms; tumor recurrence; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Doxorubicin; Female; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Polyethylene Glycols; Triple Negative Breast Neoplasms |
顯示於: | 基因體暨蛋白體醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。